These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 24412596)
61. Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. Buckler JL; Walsh PT; Porrett PM; Choi Y; Turka LA J Immunol; 2006 Oct; 177(7):4262-6. PubMed ID: 16982858 [TBL] [Abstract][Full Text] [Related]
62. IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Zhang X; Kiapour N; Kapoor S; Khan T; Thamilarasan M; Tao Y; Cohen S; Miller R; Sobel RA; Markovic-Plese S J Immunol; 2019 Sep; 203(5):1142-1150. PubMed ID: 31341075 [TBL] [Abstract][Full Text] [Related]
63. Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients. Capone A; Bianco M; Ruocco G; De Bardi M; Battistini L; Ruggieri S; Gasperini C; Centonze D; Sette C; Volpe E Cells; 2019 Jun; 8(6):. PubMed ID: 31167379 [TBL] [Abstract][Full Text] [Related]
64. Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis. Nielsen CH; Börnsen L; Sellebjerg F; Brimnes MK PLoS One; 2016; 11(1):e0146971. PubMed ID: 26756931 [TBL] [Abstract][Full Text] [Related]
66. Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding. Yao K; Graham J; Akahata Y; Oh U; Jacobson S J Neuroimmune Pharmacol; 2010 Sep; 5(3):469-78. PubMed ID: 20661655 [TBL] [Abstract][Full Text] [Related]
70. Endogenous interleukin-6 amplifies interleukin-17 production and corticoid-resistance in peripheral T cells from patients with multiple sclerosis. Ferreira TB; Hygino J; Barros PO; Teixeira B; Kasahara TM; Linhares UC; Lopes LM; Vasconcelos CC; Alvarenga R; Wing AC; Andrade RM; Andrade AF; Bento CA Immunology; 2014 Dec; 143(4):560-8. PubMed ID: 24919524 [TBL] [Abstract][Full Text] [Related]
71. Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis. Dolati S; Ahmadi M; Rikhtegar R; Babaloo Z; Ayromlou H; Aghebati-Maleki L; Nouri M; Yousefi M Int Immunopharmacol; 2018 Aug; 61():74-81. PubMed ID: 29852475 [TBL] [Abstract][Full Text] [Related]
72. Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis. Mohamed MS; Nahrery EMAE; Shalaby N; Hussein M; Aal RAE; Mohamed MM Mult Scler Relat Disord; 2019 Feb; 28():226-229. PubMed ID: 30623862 [TBL] [Abstract][Full Text] [Related]
73. Distinct Cytokine and Chemokine Expression in Plasma and Calpeptin-Treated PBMCs of a Relapsing-Remitting Multiple Sclerosis Patient: A Case Report. Chandran R; Capone M; Matzelle D; Polcyn R; Kau E; Haque A; Banik NL Neurochem Res; 2018 Dec; 43(12):2224-2231. PubMed ID: 30291537 [TBL] [Abstract][Full Text] [Related]
75. [Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example Sema4D and CD72]. Danchenko IY; Baidina TV; Kuklina EM; Trushnikova TN; Nekrasova IV Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):63-71. PubMed ID: 31934990 [TBL] [Abstract][Full Text] [Related]
76. IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis. Setiadi AF; Abbas AR; Jeet S; Wong K; Bischof A; Peng I; Lee J; Bremer M; Eggers EL; DeVoss J; Staton T; Herman A; von Büdingen HC; Townsend MJ J Neuroimmunol; 2019 Jul; 332():147-154. PubMed ID: 31034962 [TBL] [Abstract][Full Text] [Related]